Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 54: 785-787, 2008. First published March 28, 2008; 10.1373/clinchem.2008.105254
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.105254v1
54/5/785    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reaven, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reaven, G.
Related Collections
Right arrow Perspective
(Clinical Chemistry. 2008;54:785-787.)
© 2008 American Association for Clinical Chemistry, Inc.


Perspective

Why a Cluster is Truly a Cluster: Insulin Resistance and Cardiovascular Disease

Gerald Reavena

1 Stanford University School of Medicine, Stanford, CA

aAddress correspondence to this author at: Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford Medical Center, Falk CVRC, 300 Pasteur Drive, Stanford, CA 94305. Fax 650-725-1599; e-mail greaven@cvmed.stanford.edu.

The first 20% of the full text of this article appears below.

The 2 major definitions of the metabolic syndrome (MetS) are based on disparate views as to the etiology of this diagnostic category. Proponents of the Adult Treatment Panel III (ATP 3) version(1) consider this entity to be "truly is a syndrome," a grouping of atherosclerotic cardiovascular disease risk factors that probably has more than one cause. In contrast, adherents to the International Diabetes Federation (IDF) definition feel that there is a specific cause of their version of the MetS(2), stating that "central obesity is an early step in the etiological cascade leading to the full metabolic syndrome."

I believe the view expressed by the proponents of the ATP III version of the MetS that there is no single "cause" of the components is true at the most simplistic level, but misleading, whereas the notion that abdominal obesity is the "cause" of these components, as expressed by the adherents to the IDF version, can be challenged.


one or multiple causes of the mETs?

The fundamental question is whether there is one root cause that can explain the clustering of the components that comprise the various metabolic conditions thought to indicate the presence of the MetS, not whether any individual component can have more than one cause. It is obvious that any of these individual metabolic abnormalities, e.g., glucose intolerance, high triglyceride (TG) or low HDL cholesterol (HDL-C) concentration, and high blood pressure, can have more than one cause. For example, hypertriglyceridemia can result from a deficiency of lipoprotein lipase and hypertension from renal artery stenosis. Ample evidence exists, however, that insulin resistance and compensatory hyperinsulinemia increase the risk of all of these individual metabolic abnormalities, and I know of no other mechanistic explanation that fulfills that role. The substantial evidence in support of this view cannot be summarized in the context of . . . [Full Text of this Article]


how central is central obesity?


Conclusions




The following articles in journals at HighWire Press have cited this article:


Home page
Arch NeurolHome page
S. Craft
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Arch Neurol, March 1, 2009; 66(3): 300 - 305.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.